November 15, 2019
Article
Richard Furie, MD, chief of the division of rheumatology with Norwell Health, discusses the results of a phase 2 trial examining obinutuzumab for lupus nephritis.
Philip Mease, MD, director of rheumatology research at the Swedish Rheumatology Research Group, discusses the current state of treatments for psoriatic arthritis.
November 14, 2019
Elaine Husni, MD, discusses the results of a trial she led examining quality of life changes in psoriatic arthritis patients receiving golimumab over a 1-year period.
John Sundy, MD, PhD, senior vice president of Inflammation and Respiratory Disease with Gilead Sciences, discusses the results of a pooled safety analysis examining phase 3 studies of filgotinib.
Raymond Douglas, MD, PhD, discusses teprotumumab and its potential for treating thyroid eye disease.
Peter Izmirly, MD, discusses the results of a trial he led examining the possible reduction in recurrence of congenital heart block from treatment with hydroxychloroquine at ACR 2019.
Renowned infectious disease expert Leonard Calabrese, DO, professor of medicine at the Cleveland Clinic Lerner College of Medicine, takes part in a Q&A on vaccinations in immunocompromised patient populations.
Aileen Pangan, MD, executive medical director of Immunology with AbbVie, discusses the results of the SELECT-AXIS 1 trial and what it indicates about upadacitinib as a treatment for ankylosing spondylitis.
Jianmin Fang, PhD, CEO and founder of Remegen Ltd., discusses the results of a phase 2b trial exmaining the use of telitacicept for the treatment of SLE.
November 13, 2019
Yusuf Yazici, MD, chief medical officer of Samumed, discusses SM04690(Lorecivivint) at ACR 2019.
